Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations

27 Jun 2017

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Circulating tumor cells (CTC) in the blood are hypothesized as the means of systemic tumor spread. Blood obtained from healthy donors and patients with PDAC was therefore subject to size-based CTC-isolation. We additionally compared Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in pancreatic CTC and corresponding tumors, and evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28674438
DOI: 10.1038/s41598-017-04601-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS MutationsPMID 28674438Read ↗

KRAS mutations in pancreatic circulating tumor cells: a pilot study.Semantic proximity Read ↗

Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.Semantic proximity Read ↗

Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.Semantic proximity Read ↗

Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.Semantic proximity Read ↗

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.Semantic proximity Read ↗

Prognostic Role of Specific KRAS Mutations Detected in Aspiration and Liquid Biopsies from Patients with Pancreatic Cancer.Semantic proximity Read ↗

Circulating tumor cells found in patients with localized and advanced pancreatic cancer.Semantic proximity Read ↗

Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.Semantic proximity Read ↗

Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.Semantic proximity Read ↗

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Extracellular vesicles are the primary source of blood‐borne tumour‐derived mutant KRAS DNA early in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.